Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500295 | 0.91 | MAPT (0.48) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6064507 | 0.79 | CCKBR (0.63) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6489556 | 0.78 | CCKBR (0.58) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6501963 | 0.78 | CCKBR (0.56) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6064529 | 0.76 | CCKBR (0.59) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6065076 | 0.76 | CCKBR (0.64) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6064921 | 0.76 | CCKBR (0.64) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6065068 | 0.75 | CCKBR (0.59) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6158876 | 0.71 | CCKBR (0.64) | CCKBRMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6159682 | 0.71 | CCKBR (1.00) | CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956053-B2 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | THE JAMES BLACK FOUNDATION LIMITED (GB) | 2005-10-18 | — | — | US | disclosed |
| US-20030207874-A1 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | JAMES BLACK FOUNDATION LIMITED, THE (GB) | 2003-11-06 | — | — | US | disclosed |
| WO-2001090078-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS GASTRIN AND CHOLECYSTOKIN IN RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207874-A1 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | CCKBR, GRPR, CCKAR | CCKBR 1/4885MEN1 411/4885NPC1 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.